Sarcopenia does not limit overall survival in patients with colorectal liver metastases undergoing interstitial brachytherapy
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 01.03.2023 · 195 (03) · 217-223
DOI: 10.1055/a-1936-2937 ↗Kurz gefasst
Fachartikel in der Zeitschrift RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, erschienen am 01.03.2023. Verfasst von Maximilian Thormann und 7 weiteren Autor:innen. Beteiligte Einrichtung: University Clinic for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany. Hauptthemen laut MEDLINE: Sarcopenia, Brachytherapy, Liver Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Purpose
Several studies report an association of sarcopenia with survival in oncologic patients. The aim of this study is to assess the influence of sarcopenia on overall survival (OS) in patients with colorectal liver metastases undergoing interstitial brachytherapy (iBT)
Methods
We identified 144 patients with colorectal liver metastases from our database from 2014–2017. Computed tomography (CT) chest scans at the L3 level were retrospectively analyzed. Psoas muscle area (PMA), psoas muscle index (PMI), and skeletal muscle gauge (SMG) were measured on the CT scan before treatment. Parameters were associated with overall survival.
Results
116 patients were included. Median overall survival was 27 months. Median PMA was 13.79 cm2, median PMI 4.51 cm2/m2. Neither PMA (HR 1.036, 95 % CI 0.996–1.078, p = 0.080), PMI (HR 1.068, 95 % CI 0.922–1.238, p = 0.382), nor SMG (HR 1.00, 95 % CI 0.998–1.003, p = 0.955) were significantly associated with overall survival.
Conclusion
Sarcopenic patients undergoing iBT for colorectal liver metastases did not show decreased overall survival. If confirmed by comparative studies, sarcopenia may serve as a biomarker for treatment decision in patients with CRLM. Key points: Sarcopenia is not a risk factor for survival in patients with CLRM undergoing iBT. Citation Format
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- University Clinic for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany.
Zitieren
APA
Thormann, M., Heitmann, F., Wrobel, V., Barajas Ordonez, F., Pech, M., Surov, A., Damm, R., & Omari, J. (2023). Sarcopenia does not limit overall survival in patients with colorectal liver metastases undergoing interstitial brachytherapy. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 195(03), 217-223. https://doi.org/10.1055/a-1936-2937
Vancouver
Thormann M, Heitmann F, Wrobel V, Barajas Ordonez F, Pech M, Surov A, et al. Sarcopenia does not limit overall survival in patients with colorectal liver metastases undergoing interstitial brachytherapy. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2023;195(03):217-223. doi:10.1055/a-1936-2937
BibTeX
@article{Thormann2023,
author = {Thormann, Maximilian and Heitmann, Franziska and Wrobel, Vanessa and Barajas Ordonez, Felix and Pech, Maciej and Surov, Alexey and Damm, Robert and Omari, Jazan},
title = {Sarcopenia does not limit overall survival in patients with colorectal liver metastases undergoing interstitial brachytherapy},
journal = {RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren},
year = {2023},
volume = {195},
number = {03},
pages = {217--223},
doi = {10.1055/a-1936-2937}
}
EUVIMED